Ascletis Pharma Inc. (Ascletis) has issued a voluntary announcement confirming three poster presentations at the 33rd European Congress on Obesity (ECO 2026), scheduled for 12–15 May 2026 in Istanbul. All data are drawn directly from the company’s disclosure.

Ascletis will present Phase I results for ASC47, an adipose-targeting thyroid hormone receptor-β agonist designed for muscle-preserving weight loss. In combination with semaglutide, ASC47 delivered up to 111.80% greater relative weight loss in participants with obesity compared with semaglutide monotherapy.

Pre-clinical data will also be released on ASC36, a once-monthly next-generation amylin receptor agonist peptide. In non-human primate studies, ASC36 achieved a 32-day average observed half-life—six times longer than petrelintide—and produced 91% greater relative weight loss than petrelintide in diet-induced obese (DIO) rat models.

A third poster will cover ASC35, a once-monthly GLP-1R/GIPR dual agonist peptide. In non-human primates, ASC35 recorded a 14-day average observed half-life—six times longer than tirzepatide—and achieved 71% greater relative weight loss than tirzepatide in DIO mouse models.

All three presentations fall under Track 4: Obesity Management and Intervention and will be held on Thursday, 14 May 2026, from 18:00 to 19:15 TRT. Ascletis cautions that successful development, manufacturing and commercialisation of ASC47, ASC36 and ASC35 are not guaranteed.